Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [41] The Concept of the Polypill in the Prevention of Cardiovascular Disease
    Wiley, Brandon
    Fuster, Valentin
    ANNALS OF GLOBAL HEALTH, 2014, 80 (01): : 24 - 34
  • [42] Medication adherence to secondary prevention for coronary artery disease
    Rossi, Emiliano
    Perman, Gaston
    Michelangelo, Hernan
    Alonzo, Claudia B.
    Brescacin, Laura
    Kopitowski, Karin S.
    Navarro Estrada, Jose L.
    MEDICINA-BUENOS AIRES, 2014, 74 (02) : 99 - 103
  • [43] The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review
    Gandapur, Yousuf
    Kianoush, Sina
    Kelli, Heval M.
    Misra, Satish
    Urrea, Bruno
    Blaha, Michael J.
    Graham, Garth
    Marvel, Francoise A.
    Martin, Seth S.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2016, 2 (04) : 237 - 244
  • [44] PREDICTORS OF MEDICATION ADHERENCE IN THE SETTING OF A PRIMARY CARDIOVASCULAR PREVENTION PROGRAM
    Masnaghetti, S.
    Pedretti, R.
    Braga, S. Sarzi
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0G) : G185 - G185
  • [45] Use of the cardiovascular polypill 40 mg in secondary cardiovascular prevention
    Marzal, Domingo
    Rodriguez Padial, Luis
    Arnaiz, Joan-Albert
    Castro, Almudena
    Cosin, Juan
    Lekuona, Inaki
    Guijarro, Carlos
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2018, 30 (05): : 240 - 247
  • [46] POLYPILL STRATEGY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS
    Dabhadkar, K. C.
    Bellam, N.
    DRUGS OF TODAY, 2013, 49 (05) : 317 - 324
  • [47] Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars)
    Malekzadeh, Fatemeh
    Gandomkar, Abdullah
    Poustchi, Hossein
    Etemadi, Arash
    Roshandel, Gholamreza
    Attar, Armin
    Abtahi, Firoozeh
    Boogar, Shahrokh Sadeghi
    Mohammadkarimi, Vahid
    Fattahi, Mohammad Reza
    Mohagheghi, Abbas
    Malekzadeh, Reza
    Sepanlou, Sadaf G.
    HEART, 2024, 110 (14) : 940 - 946
  • [48] A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease
    Al-Abdouh, Ahmad
    Mhanna, Mohammed
    Jabri, Ahmad
    Ahmed, Taha
    Altibi, Ahmed M.
    Ghanem, Fares
    Alhuneafat, Laith
    Mostafa, Mostafa Reda
    Abusnina, Waiel
    Dewaswala, Nakeya
    Bhopalwala, Huzefa
    Kundu, Amartya
    Michos, Erin D.
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (02) : e193 - e195
  • [49] Cardiovascular Disease in Women Primary and Secondary Cardiovascular Disease Prevention
    Sanghavi, Monika
    Gulati, Martha
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2016, 43 (02) : 265 - +
  • [50] The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis
    Salim, Hamza
    Musmar, Basel
    Saifi, Motaz
    Ayyad, Mohammed
    Ruzieh, Mohammed
    Azar, Jehad
    Nazzal, Zaher
    CURRENT CARDIOLOGY REVIEWS, 2024, 20 (02) : 61 - 71